Biosynthetic Cocaine? PharmaDrug Files Patent For Novel Manufacturing Method
FULL DISCLOSURE: This content is sponsored by PharmaDrug Inc.
PharmaDrug’s (CSE: PHRX) subsidiary SecureDose has finally revealed its first biosynthetic formulation: pharmaceutical grade cocaine.
SecureDose is reportedly initiating work on a novel manufacturing method for the commercial-scale production of cocaine, which will be produced to support safe supply programs.
“We have seen the proliferation of safe supply programs in both Canada and around the world. While opioid addiction is a serious problem, there exists a supply chain that provides both natural and synthetic opioid products for those programs,” commented Robert Steen, CEO of PharmaDrug.
“Cocaine, however, is the illegal drug that causes the most cost and harm to society barring opioids according to the Canadian Centre for Substance Use and Addiction, causing $4.2 Billion1 in harm in Canada annually – but there is no supply chain to alleviate these harms.”
READ: PharmaDrug Names Dr David Kideckel As Chairman, While SecureDose Finalizes Formulation
A patent has been filed for a method of development that uses biosynthetic chemistry that the company believes will allow for the use of GMP manufacturing in the production of pharmaceutical grade cocaine. The intent is that the resulting product will be a reliable, regulated, clinically manufactured product that is suitable for use in safe supply programs.
A lab has already been identified by the company that will be used for the development of the novel process. An accelerated development timeframe is being pursued by the lab, with the manufacturing process to target the cost effective and efficient production of cocaine.
PharmaDrug last traded at $0.06 on the CSE.
FULL DISCLOSURE: PharmaDrug is a client of Canacom Group, the parent company of The Deep Dive. Canacom Group is currently long the equity of PharmaDrug. The author has been compensated to cover PharmaDrug on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
As the founder of The Deep Dive, Jay is focused on all aspects of the firm. This includes operations, as well as acting as the primary writer for The Deep Dive’s stock analysis. In addition to The Deep Dive, Jay performs freelance writing for a number of firms and has been published on Stockhouse.com and CannaInvestor Magazine among others.
